Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses (Q64125847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Kentaro Sumida

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Daiko Wakita

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Yoshinori Narita

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kazutaka Masuko

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Satoshi Terada

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kazue Watanabe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Takayuki Satoh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Hidemitsu Kitamura

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Takashi Nishimura

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

2060-2072

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Multiple roles for CD4+ T cells in anti-tumor immune responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

STATs in cancer inflammation and immunity: a leading role for STAT3

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

3-Methylcholanthrene-induced transforming growth factor-beta-producing carcinomas, but not sarcomas, are refractory to regulatory T cell-depletion therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

The role of myeloid cells in the promotion of tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Myeloid cell population dynamics in healthy and tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Serum interleukin-6 levels reflect the disease status of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

NF-kappaB: linking inflammation and immunity to cancer development and progression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Interleukin-6 trans-signalling in chronic inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

The soluble Interleukin 6 receptor: generation and role in inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

IFN-gamma-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201142335

7 January 2021

Identifiers

DOI

10.1002/EJI.201142335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22653638%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference